Iris Pittman
National Institutes of Health(US)National Institute of Allergy and Infectious Diseases(US)
Publications by Year
Research Areas
HIV Research and Treatment, SARS-CoV-2 and COVID-19 Research, Mosquito-borne diseases and control, Malaria Research and Control, Influenza Virus Research Studies
Most-Cited Works
- → Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite Vaccine(2013)772 cited
- → Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials(2017)300 cited
- → Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial(2022)157 cited
- → Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study(2019)125 cited
- → Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria(2022)115 cited
- → Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial(2019)105 cited
- → An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults(2023)92 cited
- → Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial(2022)86 cited
- → Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial(2021)63 cited
- → Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials(2024)18 cited